<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1199">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343248</url>
  </required_header>
  <id_info>
    <org_study_id>RM08-3006</org_study_id>
    <nct_id>NCT04343248</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19
      and other VRIs in elderly LTCF residents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and
      safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF
      residents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic laboratory-confirmed COVID-19</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic laboratory-confirmed VRI</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>COVID-19</condition>
  <condition>Viral Respiratory Illnesses</condition>
  <arm_group>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo tablets orally twice daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide 600 mg administered orally twice daily for six weeks</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>NTZ (nitazoxanide)</other_name>
    <other_name>NT-300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally twice daily for six weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin Super B-Complex</intervention_name>
    <description>Vitamin Super B-Complex administered orally twice daily to maintain the blind</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female residents of LTCFs at least 55 years of age.

          -  Willing and able to provide written informed consent and comply with the requirements
             of the protocol.

          -  At least one symptomatic laboratory-confirmed COVID-19 illness identified among
             residents or staff of the LTCF within 10 days prior to randomization.

        Exclusion Criteria:

          -  Alzheimer's disease, dementia, or other mental incapacity which precludes
             comprehension of the study requirements or symptom diary.

          -  Subjects expected to require hospitalization within the 8-week treatment and follow-up
             period.

          -  Subjects with a history of COVID-19 or known to have developed anti-SARS- CoV-2
             antibodies.

          -  Subjects who experienced a previous episode of acute upper respiratory tract
             infection, otitis, bronchitis or sinusitis or received antibiotics for these
             conditions or antiviral therapy for influenza within two weeks prior to and including
             study day 1.

          -  Receipt of any dose of NTZ within 7 days prior to screening.

          -  Treatment with any investigational drug or vaccine within 30 days prior to screening
             or unwilling to avoid them during the course of the study.

          -  Known sensitivity to NTZ or any of the excipients comprising the study medication.

          -  Subjects unable to swallow oral tablets or capsules.

          -  Subjects taking medications considered to be major CYP2C8 substrates.

          -  Subjects who, in the judgment of the Investigator, will be unlikely to comply with the
             requirements of this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Bardin, PharmD, BCPS</last_name>
    <phone>813-282-8544</phone>
    <email>matthew.bardin@romark.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chappel Group Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Specialists, Inc.</name>
      <address>
        <city>Acworth</city>
        <state>Georgia</state>
        <zip>30101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romark</last_name>
      <phone>877-925-4642</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Viral Respiratory Illnesses</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

